For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Centrexion Therapeutics Corporation

USPTO Granted Patents = 36

CIPO Patents = 1

EPO Patents = 10

Trademarks = 2

Forward Citations = 99

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

James N Campbell (11 out of 17 patents)

Henri Doods (9 out of 76 patents)

Riccardo Giovannini (9 out of 63 patents)

4. Rocco Mazzaferro (9 out of 16 patents)

5. Drazen Ostovic (6 out of 15 patents)

6. Gary Fred Musso (6 out of 24 patents)

7. Doris Riether (6 out of 49 patents)

8. Florian Paul Christian Binder (6 out of 18 patents)

9. Janet Rachel Nicholson (6 out of 13 patents)

10. Achim Sauer (6 out of 18 patents)

11. Marco Santagostino (5 out of 37 patents)

12. Kai Gerlach (5 out of 38 patents)

13. Stefan Scheuerer (5 out of 25 patents)

14. Thomas Trieselmann (5 out of 20 patents)

15. Sara Frattini (5 out of 34 patents)

36 patents: Sort by Forward Citations

1. 12344601 - (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles (2025-07-01),

2. 12268679 - Compositions and methods for epidural administration of MCOPPB for pain relief (2025-04-08),

3. 12209094 - CCR2 receptor antagonists and uses thereof (2025-01-28),

4. 12201594 - Methods and compositions for treatment of pain using capsaicin (2025-01-21),

5. 12076321 - (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate (2024-09-03),

6. 11992470 - Stable aqueous capsaicin injectable formulations and medical uses thereof (2024-05-28),

7. 11872219 - Compositions and methods for intrathecal administration of MCOPPB for pain relief (2024-01-16),

8. 11820727 - Capsaicinoid prodrug compounds and their use in treating medical conditions (2023-11-21),

9. 11731981 - CCR2 receptor antagonists and uses thereof (2023-08-22),

10. 11725004 - (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles (2023-08-15),

11. 11517546 - High concentration local anesthetic formulations (2022-12-06),

12. 11447444 - Capsaicinoid prodrug compounds and their use in treating medical conditions (2022-09-20),

13. 11344516 - Stable aqueous capsaicin injectable formulations and medical uses thereof (2022-05-31),

14. 11254659 - Capsaicinoid prodrug compounds and their use in treating medical conditions (2022-02-22),

15. 11147814 - (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate (2021-10-19),

Centrexion Therapeutics Corporation is a biopharmaceutical company focused on developing non-opioid, non-surgical therapies for chronic pain. Their goal is to provide innovative treatments that address the underlying mechanisms of pain and improve quality of life for patients. With a team of experienced researchers and clinicians, Centrexion is dedicated to advancing the understanding and treatment of chronic pain through their cutting-edge scientific approach.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

36 Patents

#67 in Boston, MA

#539 in Massachusetts

#9,191 in US

#18,178 in the World

Boston, MA, United States of America

Centrexion Therapeutics Corporation

Forward Citations = 99

34 inventors:

James N Campbell (11 out of 17 patents)

Henri Doods (9 out of 76 patents)

Riccardo Giovannini (9 out of 63 patents)

4. Rocco Mazzaferro (9 out of 16 patents)

5. Drazen Ostovic (6 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…